Carfilzomib/Pomalidomide Regimen Warrants Further Investigation in Refractory Multiple Myeloma

Wayne Kuznar
Published: Saturday, Jun 04, 2016

At the end of 1 cycle, 65% of all response-evaluable patients and 61% of the primary study population were already in PR or better. Depth of response improved with continued treatment. On intent-to-treat analysis, 84% achieved PR or better, with 21 of 30 planned patients being treated at MTD.

After a median of 17.9 months of follow-up, median PFS in the overall study population was 12.9 months and median overall survival had not been reached. At 24 months, 78% of patients were still alive.

With only limited data on the activity of established regimens in patients with multiple myeloma who progress on lenalidomide, further exploration of the KPd regimen in a randomized setting is warranted, said Jakubowiak.
Rosenbaum CA, Stephens LA, Kukreti V, et al. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study. Presented at: ASCO 2016; June 3-7, 2016; Chicago. Abstract 8007.
<<< View more from the 2016 ASCO Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication